Recruiting NCT06603597
HER2-positive Breast Cancer Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: HER2 + Breast Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective Evaluation of Outcomes for HER2-positive Breast Cancer (PRO-HER2)
Overview
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
Primary outcome measures
- Overall survival rate [Time frame: From diagnosis to 5 years after diagnosis]
Secondary outcome measures (1)
- Pathologic complete response rate [Time frame: From start of neoadjuvant systemic treatment until approximately 8 months after start of neoadjuvant systemic treatment]
Eligibility criteria
Inclusion criteria
- Stage I-IV HER2-positive breast cancer
Exclusion criteria
- None
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 6 centers
- KUCC - Indian Creek — Overland Park
- KUCC - Overland Park — Overland Park
- KUCC - Briarcliff — Westwood
- KUCC - Olathe — Westwood
- The University of Kansas Cancer Center — Westwood
- KUCC - Lee's Summit — Lee's Summit
Identifiers
NCT: NCT06603597 · 160944